Company intelligence / Profile preview

Crossignal Therapeutics

La Jolla, California, United Statescrossignaltherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Crossignal Therapeutics develops a new generation of small molecule immunotherapies targeting immune cell-expressed tumor metabolic factor GPCRs to overcome cancer immune escape. Their lead asset CT3001 targets GPR35 and has entered Phase 1/2 clinical trials for advanced solid tumors. Additional programs include adenosine receptor antagonists and early-stage discovery efforts leveraging their proprietary PPS assay platform. The company holds full IP and global commercial rights to its assets.

Therapeutic areas: Oncology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

3 assets

ct3001

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Crossignal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crossignal Therapeutics.

Explore the full profile